Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study

Launched by FIRST AFFILIATED HOSPITAL XI'AN JIAOTONG UNIVERSITY · Apr 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying patients with blood diseases who are undergoing a specific type of treatment called allogeneic hematopoietic stem cell transplantation (allo-HSCT). The researchers want to learn more about certain blood markers that could help them understand and predict complications that might occur after the transplant, such as a serious condition called acute graft versus host disease (where the new cells attack the patient’s body), kidney problems, and heart issues. The study will follow 500 patients over 100 days, checking their health weekly and taking blood samples at several points to look for changes that might indicate complications.

To be eligible for this trial, participants should be 65 years old or younger, have normal heart and kidney function before the transplant, and have a need for this specific treatment. However, individuals with certain health issues, such as kidney problems or a history of serious heart conditions, cannot participate. If someone joins the study, they can expect regular check-ups and blood tests to monitor their health closely during the first few months after their transplant. This research aims to improve understanding of early complications and help doctors provide better care for patients undergoing this important treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≤ 65 years old;
• • Gender unlimited;
• • Normal heart and kidney function before transplantation;
• • Patients with indications for allogeneic hematopoietic stem cell transplantation.
• Exclusion Criteria:
• • CREA or BUN higher than the normal upper limit value before transplantation;
• • Individuals with a history of arrhythmia, heart failure, or PCI stent implantation prior to transplantation;
• • Patients with mental illness;
• • Those who are unwilling to sign informed consent.